<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02393482</url>
  </required_header>
  <id_info>
    <org_study_id>AMENORREA</org_study_id>
    <nct_id>NCT02393482</nct_id>
  </id_info>
  <brief_title>Psychological Impact of Amenorrhea in Women With Endometriosis</brief_title>
  <official_title>Psychological Impact of Amenorrhea in Women With Endometriosis: Perspective Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cagliari</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cagliari</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the impact on quality of life, psychological health,
      sexuality and chronic pain of therapies which determine amenorrhea in symptomatic women with
      endometriosis, through the administration of self reported questionnaires. Amenorrhea in the
      first group is caused by balanced assumption of estroprogestins, in the second group is
      caused by GnRHa-induced hypoestrogenism.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life (self reported questionnaires)</measure>
    <time_frame>180 days</time_frame>
    <description>This outcome will be evaluated through self reported questionnaires</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sexual health (self reported questionnaires)</measure>
    <time_frame>180 days</time_frame>
    <description>This outcome will be evaluated through self reported questionnaires</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Psychological impact (self reported questionnaires)</measure>
    <time_frame>180 days</time_frame>
    <description>This outcome will be evaluated through self reported questionnaires</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Amenorrhea</condition>
  <condition>Endometriosis</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Balanced estroprogestins</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women assigned to this arm will assume balanced monophasic estroprogestins (etinil-estradiol 100 mcg/levonorgestrel 20 mcg), one tablet orally daily, for 180 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GnRHa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women assigned to this arm will assume Leuprorelin acetate (3,75 mg/2ml), one intramuscular administration every 28 days. After 45 days of treatment, therapy will be implemented with Tibolone 5 mg, one tablet daily orally, and Calcium carbonate/colecalciferol (500 mg/400 UI), one tablet daily orally. This therapy will be prosecuted for the remaining 135 days of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estroprogestinic therapy (Etinil-estradiol/levonorgestre)</intervention_name>
    <description>Etinil-estradiol/levonorgestrel (100 mcg/20 mcg)/die</description>
    <arm_group_label>Balanced estroprogestins</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonadotropin-releasing hormone agonist (Leuprorelin acetate)</intervention_name>
    <description>Leuprorelin acetate (3,75 mg/2 ml)/month</description>
    <arm_group_label>GnRHa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Add back therapy 1 (tibolone)</intervention_name>
    <description>tibolone 5 mg/die</description>
    <arm_group_label>GnRHa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Add back therapy 2 (calcium carbonate/colecalciferol)</intervention_name>
    <description>calcium carbonate/colecalciferol (500mg/400UI)/die</description>
    <arm_group_label>GnRHa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical, echographical or surgical diagnosis of endometriosis

        Exclusion Criteria:

          -  Comorbidity

          -  Psychiatric diseases

          -  Refusal or inability to sign informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Cagliari,Obstetrics and Gynecological Department,</name>
      <address>
        <city>Monserrato</city>
        <state>Cagliari</state>
        <zip>09042</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>McWilliams LA, Cox BJ, Enns MW. Mood and anxiety disorders associated with chronic pain: an examination in a nationally representative sample. Pain. 2003 Nov;106(1-2):127-33.</citation>
    <PMID>14581119</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2015</study_first_submitted>
  <study_first_submitted_qc>March 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2015</study_first_posted>
  <last_update_submitted>March 8, 2016</last_update_submitted>
  <last_update_submitted_qc>March 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cagliari</investigator_affiliation>
    <investigator_full_name>Stefano Angioni</investigator_full_name>
    <investigator_title>MD,PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
    <mesh_term>Amenorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Tibolone</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

